(SNCE) – Globe Newswire
-
Kuehn Law Encourages KAMN, SNCE, KRTX, and BATL Investors to Contact Law Firm
-
Kuehn Law Encourages SNCE, MGRC, VINE, and KRTX Investors to Contact Law Firm
-
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
-
Science 37 Receives Top Honors in Everest PEAK Matrix®
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Third Quarter 2023 Financial Results
-
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
-
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
-
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
-
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
-
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
-
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Second Quarter 2023 Financial Results
-
Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023
-
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"
-
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"
-
Science 37 Reports First Quarter 2023 Financial Results
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot
-
Science 37 Joins Partnership in Support of White House CancerX and Cancer Moonshot
-
Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023
-
Science 37 to Report First Quarter 2023 Financial Results on May 15, 2023
-
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
-
Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity
-
Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
-
Science 37 Collaborates with AWS to Enable Faster, Patient-Friendly, Clinical Research
-
Science 37 Adds New Head of Quality, Irena Lambridis
-
Science 37 Adds New Head of Quality, Irena Lambridis
-
Science 37 to Host Business Update Call on April 12, 2023
-
Science 37 to Host Business Update Call on April 12, 2023
-
Science 37 Unveils Three Global Centers of Excellence to Drive Efficiency, Speed and Quality
-
Science 37 Unveils Three Global Centers of Excellence to Drive Efficiency, Speed and Quality
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
-
Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results
-
Science 37 Reports Fourth Quarter and Full Year 2022 Financial Results
-
Science 37 to Present at the Cowen 43rd Annual Health Care Conference
-
Science 37 to Present at the Cowen 43rd Annual Health Care Conference
-
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023
-
Science 37 to Report Fourth Quarter 2022 Financial Results on March 6, 2023
Back to SNCE Stock Lookup
